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Populärvetenskaplig sammanfattning 
När man talar om högt blodtryck menar man oftast det som mäts i armens blodkärl. Högt 
blodtryck enbart i lungorna är mer ovanligt och det rör sig då istället om sjukdomen pulmonell 
hypertension, vars namn betyder just högt blodtryck i lungorna.  
Hjärtat är indelat i två sidor, höger och vänster. När blodtrycket i lungorna är förhöjt är det 
höger hjärthalva som måste jobba extra hårt. Detta stressar högerhjärtat som normalt är svagare 
än vänster sida. Högerhjärtat kan dock växa till och bli starkare, men bara till en viss gräns. 
Därefter orkar inte hjärtat jobba emot sjukdomen i lungorna och resultatet blir allvarligt med 
hjärtsvikt som följd.  
Pulmonell hypertension uppkommer genom att blodkärlen i lungan drar ihop sig. Sedan 
förtjockas dessa blodkärl och det blir trångt för blodet att passera. Därför stiger blodtrycket i 
lungan. Dagens mediciner förhindrar att blodkärlen drar ihop sig, vilket hjälper till viss del. 
Dessvärre avstannar inte sjukdomsprocessen och blodkärlen fortsätter att förtjockas. Pulmonell 
hypertension är en obotligt och dödligt tillstånd.  
Det finns många olika tillväxtfaktorer i kroppen. Vissa verkar på skelettet och gör att vi växer 
på längden. Andra tillväxtfaktorer verkar på blodkärlen och leder till ovan nämnda 
förtjockning. Normala blodkärl består av både celler och bindväv och vid pulmonell 
hypertension blir cellerna fler och mängden bindväv ökar. I denna avhandling har jag 
tillsammans med kollegor studerat hur samspelet mellan bindväv och tillväxtfaktorer påverkar 
cellernas funktion och sjukdomens utveckling.  
Hos patienter kan vi studera om vissa tillväxtfaktorer eller molekyler i bindväven är förändrade. 
För att testa om dessa faktorer spelar någon roll behövs en modell för pulmonell hypertension. 
Därför utsätter vi möss för syrebrist, något som närmast liknar höghöjdsträning motsvarande 
6000 meter över havet. Lungans blodkärl reagerar på syrebristen och mössen får pulmonell 
hypertension. Hos möss är det dessutom möjligt att ta bort en molekyl i taget genom att slå ut 
en viss gen i arvsmassan. Vi har bland annat undersökt en specifik molekyl i bindväven, 
perlecan, som kan binda tillväxtfaktorer som till exempel PDGF-B. Den första och andra 
artikeln i denna avhandling beskriver hur detta påverkar förtjockningen av lungans blodkärl. I 
de två andra artiklarna kartlägger vi en mer nyupptäckt tillväxtfaktor, PDGF-D, i normal 
utveckling och vid utveckling av pulmonell hypertension. 
Studierna i denna avhandling handlar främst om att bättre förstå biologin vid uppkomst av 
pulmonell hypertension. Mycket forskning är just nu fokuserad på tillväxtfaktorer och denna 
avhandling understryker vikten av att också ta med bindväven i beräkningarna. Vårt mål är att 
bidra med kunskap till utveckling av mer specifik behandling som är så effektiv och skonsam 
som möjligt för patienter med högt blodtryck i lungorna. 
  
  
Abstract 
Pulmonary hypertension is a severe condition, leading to right heart dysfunction and preterm 
death. For pulmonary arterial hypertension (PAH), a disease group in which the primary 
pathology resides within the pulmonary pre-capillary vessels, several specific therapies are in 
clinical use, but unfortunately the prognosis is still grim. 
Available PAH therapy mainly targets vasoconstriction and the progressive vascular 
remodeling is not adequately suppressed. Considering biological similarities to malignancies, 
hypotheses and therapies from cancer research have been tested in PAH. An example of this is 
imatinib, originally designed to target a mutated receptor in chronic myeloid leukemia, and 
found to also inhibit platelet-derived growth factor (PDGF) signaling. Albeit to some extent 
efficient, imatinib is unspecific and leads to severe side effects in PAH patients. 
Previous studies have found PDGF receptor b and its ligand, PDGF-B, to be implicated in 
PAH. PDGF signaling is known to induce cell proliferation, migration, and extracellular matrix 
deposition. Additionally, PDGF-B contains a retention motif that binds to matrix 
proteoglycans, such as perlecan. Perlecan, which has previously been shown to affect vascular 
remodeling in the systemic circulation, has here been investigated in the pulmonary circulation. 
Further, the role of PDGF-D, the other known ligand of PDGF receptor b, has in this thesis 
been characterized in physiology as well as in pulmonary hypertension.  
Paper I and II combined describes how pulmonary vascular remodeling could be altered by 
either targeting the PDGF-B retention motif or perlecan heparan sulfate (HS). In development, 
perivascular smooth muscle cells and pericytes propagate towards an extracellular PDGF-B 
gradient. Our findings support previous reports on similar mechanisms also in hypoxia-induced 
pulmonary vascular remodeling. Further, we show that perlecan HS promotes fibroblast growth 
factor signaling, another important mitogen for smooth muscle cells and pericytes. 
In paper III, effects of PDGF-D deletion were thoroughly characterized. Pdgfd-/- mice were 
shown to be viable and healthy, however a mild cardiovascular phenotype, including discrete 
alterations in pericyte attachment to cardiac microvessels, was found. In Paper IV the role of 
PDGF-D in PH was explored. It was shown to be present in vascular lesions of PAH patients 
and recombinant PDGF-D potently induced proliferation of human and mouse pulmonary 
arterial smooth muscle cells in vitro. This suggested that PDGF-D could be a driver of 
pulmonary vascular remodeling. However, Pdgfd-/- mice were not protected against disease and 
hence, PDGF-D seems to be a redundant mitogen in hypoxia-induced PH. 
The collected work of this thesis highlights the importance of spatial distribution of growth 
factors and prompts future PAH studies to take the extracellular matrix into consideration. 
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1 Introduction 
1.1 Clinical introduction 
Pulmonary hypertension (PH) is a severe condition, defined by a mean pulmonary arterial 
pressure ≥ 25mmHg at rest or 30mmHg during exercise. PH can be associated with a number 
of different diseases and it is categorized into five main groups according to the World Health 
Organization classification (95). Group 1 PH, pulmonary arterial hypertension (PAH), contains 
disease subtypes with a pre-capillary / arteriolar vasculopathy. Group 2 is comprised of PH 
associated with left heart disease, group 3 associated with lung disease and/or hypoxia, group 
4 secondary to chronic thromboembolism. Group 5 is made up of a plethora of unclear and 
multifactorial types of PH. For group 2-5 PH the only available therapy so far is to treat the 
associated pathology and not the pulmonary circulation itself. However, for group 1 there is 
now an increasing number of PAH specific therapies available, but they are all far from 
curative. PAH, along with hypoxia-induced PH, is the focus of this thesis.  
PAH is a rare disease with prevalence rates varying from 11 to 26 per million adults (108). It 
exists in sporadic and hereditary forms, in which known genetic mutations are sometimes 
found. However, the penetrance is relatively low and most family member carrying the same 
mutation do not develop PAH. Further, PAH can be induced by drugs or toxins, as was first 
discovered due to the epidemy of PAH and right ventricular failure seen in France in the early 
1970’s, where subsequently the amphetamine-like diet pill, Aminorex, was found to be the 
culprit. In addition, PAH can be associated with for example connective tissue diseases 
(systemic sclerosis), HIV, schistosomiasis, portal hypertension, and congenital heart disease 
(95). Hence, within the PAH group there is great variance in pathogenesis and what joins the 
subgroups is a visually perceived similarity of the vascular lesion pathology and similar 
hemodynamics.  
In PAH, vasoconstriction, vascular remodeling, and in situ thrombosis narrow the cross-
sectional area of the pulmonary vascular tree. Pulmonary vascular resistance (PVR) is 
increased and the right ventricle (RV), normally adapted to a high compliance circulation, 
initially copes with the increased PVR and produces an elevated pressure. However, over time 
RV dysfunction and heart failure often arise. Current therapy has had significant effect on 
morbidity and mortality but prognosis is still grim. In the 1980’s, median survival for untreated 
PAH was less than three years, as compared to a recent review that found current median 
survival to be six years after diagnosis of idiopathic PAH (108). 
 
1.2 Current therapy 
PAH specific therapy, available in clinical praxis, consists of a number of agents that 
principally target four different molecular pathways; namely voltage gated calcium channels, 
nitric oxide (NO), endothelin, and the prostacyclin pathway, all of which primarily counteract 
pulmonary vasoconstriction (108).  
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Calcium channel blockade is indicated only in the small subgroup, 5-10%, of PAH patients 
who respond favorably to acute vasodilator testing during right heart catheterization. This 
group of patients differs from the rest as they have a 5-year survival rate of 90% with calcium 
channel blocking therapy alone (88, 108).  
NO induces pulmonary vasodilation by activation of soluble guanylate cyclase (sGC) that 
generates cyclic guanosine monophosphate which in turn leads to smooth muscle cell (SMC) 
relaxation. NO is useful for acute management of a pulmonary hypertensive crisis and for the 
above-mentioned acute vasodilator testing, however due to logistical challenges it is not 
administered in the outpatient setting. Instead, oral therapy stimulating sGC (Riociguat) or 
inhibiting phosphodiesterase 5 (PDE5), such as Sildenafil and Tadalafil, is used.  
Endothelin potently induces vasoconstriction and to some extent SMC proliferation and is 
overexpressed in PAH (108). Dual endothelin receptor antagonists (ERAs), such as bosentan, 
inhibit both endothelin receptor A and B. There are also A-selective antagonists, eg 
ambrisentan, available for clinical use. The rationale for avoiding inhibition of the B-receptor 
is that B-receptor signaling potentially has some vasodilatory effects (by inducing NO and 
prostacyclin production). The clinical experience and evidence for use of dual inhibition is 
however stronger. All ERAs are potentially hepatotoxic and teratogenic. Monthly liver test are 
required and therapy is aborted if liver enzymes are found to be three times the upper limit of 
normal or higher, or when signs of liver failure are observed. Bosentan also lowers serum 
concentrations of both Sildenafil and Warfarin, warranting close monitoring.  
Prostacyclin activates IP receptors, leading to elevated cyclic adenosine monophosphate that 
gives rise to relaxation of pulmonary vessels and have beneficial effects of counteracting 
thrombosis, cell proliferation and inflammation. PAH patients display attenuated levels of 
prostacyclin (108). Prostanoid agents, such as treprostinil or iloprost, activate IP receptors and 
are available for intravenous, subcutaneous, and oral administration as well as inhalation. The 
most efficient therapy (intravenous epoprostenol) has been shown to improve survival, but is 
cumbersome to administer due to its short half-life of 2-3 minutes. All prostanoids gives rise 
to several side effects such as gastrointestinal symptoms, flushing, headache, and jaw pain. The 
more potent the drug is, the more side effects unfortunately. Oral treprostinil is much easier to 
administer but has shown no add-on benefit to PAH patients already on PDE5 inhibitors and 
ERA therapy (106). Selexipag however, a recently introduced orally administered non-
prostanoid IP receptor agonist, has shown significant effects on progression of severe PAH 
(96).  
 
1.3 Neoplastic properties of PAH  
Parallel to the establishment of therapies described above, an increased research focus on anti-
proliferative strategies has taken place. 20 years ago, pioneering work of Lee et al revealed 
signs of clonal expansion of pulmonary endothelial cells (ECs) in PAH vascular lesions, 
suggesting that similar signaling pathways are in play in PAH as in cancer (65). Indeed, several 
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of the hallmarks of cancer have been found also in vascular lesions of PAH patients as well as 
in PAH animal models. Numerous signaling pathways have been implicated in these processes, 
reviewed by Boucherat et al (12), and some of these are discussed below. 
Aberrant vascular endothelial growth factor (VEGF) signaling has been observed in vascular 
lesions of PAH patients and VEGF signaling was therefore regarded as a putative therapeutic 
target. However, VEGF receptor inhibition, by the tyrosine-kinase inhibitor Su5416 Sugen, 
turned out to significantly worsen PH development when combined with chronic hypoxia 
(107). The current view is that VEGF inhibition gives rise to pulmonary EC apoptosis and that 
the remaining cells that survive have an anti-apoptotic phenotype. Later, as these ECs are 
exposed for a second hit by chronic hypoxia, this gives rise to aggravated vascular lesions and 
worsened PH. Sugen-hypoxia is now a well-established rat model of PH (104).  
Genetic mutations in the bone morphogenetic protein receptor type 2 (BMPR2) are found in 
70-80% of patients with heritable PAH. However, far from all family members, approximately 
only 20%, that carry a heterozygous BMPR2 mutation develop PAH. Mutations are also found 
in 15-25% of idiopathic PAH patients with no family history of PAH, and reduced BMPR2 
signaling is a common feature in various categories of clinical PAH as well as in animal models 
(108). Loss of BMPR2 leads to the presence of apoptosis-resistant pulmonary arterial ECs (66), 
which likely aggravate PAH development triggered by so far unidentified stimuli. Further, 
therapeutic attempts to restore BMPR2 signaling have been shown to induce apoptosis of 
pulmonary SMCs and to alleviate PH in animal models (102). A variety of genetic approaches 
have been explored, and a heterozygous BMPR2 deletion leads to mild PH which can be 
aggravated by a second hit, such as chronic hypoxia (33, 104).  
Increased interleukin 6 (IL-6), fibroblast growth factor (FGF), and platelet-derived growth 
factor (PDGF) signaling all give rise to vascular remodeling. This is true also for endothelin, 
although clinically used ERA therapy is insufficient in reversing the phenotype of pro-
proliferative, and anti-apoptotic cells. Common for IL-6, FGF, PDGF and endothelin, is that 
the signaling pathways overlap and all involve the signal transducer and activator of 
transcription-3 (STAT3), which has been found to be overly activated in cancer as well as in 
PAH (12). Interestingly, inhibition of downstream STAT3 signaling has been shown effective 
in murine models of PH (78).  
Another therapeutic strategy is to instead target the upstream receptors. A multitude of 
malignancies display an aberrant receptor tyrosine kinase activity. In chronic myeloid leukemia 
the oncoprotein BCR-Abl is for example known to induce disease. Imatinib, developed to 
selectively bind to BCR-Abl, is successfully used in clinical practice. However , imatinib is not 
entirely selective and binds and inhibits additional tyrosine kinases, like c-Kit and the PDGF 
receptors. In 2005, Schermuly et al showed remarkable efficacy of imatinib in PH rodent 
models, and suggested that this effect was primarily mediated by PDGF receptor inhibition 
(93). This success in reversing experimental pulmonary vascular remodeling gave hope 
regarding anti-proliferative therapy and receptor tyrosine kinase inhibition as promising future 
PAH therapy. However, albeit efficient in improving hemodynamics and physical capacity in 
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PAH patients, when tested in clinical trials imatinib was shown to also cause frequent and 
severe adverse effects (35, 50, 101). Imatinib was concluded not to be a suitable therapy in 
PAH patients, and this shows that caution is needed when interfering with such potent signaling 
pathways, especially in non-neoplastic disease. In cancer therapy, due to the inherent problem 
of frequent mutations and acquired therapy-resistance, broad inhibition can be preferred and 
initially perceived off-target effects might be advantageous.  
A more recently developed tyrosine kinase inhibitor, dasatinib, is similar to imatinib however 
yet more unspecific as it also inhibits Src-kinase (12). Dasatinib treatment has been shown to 
cause PAH in a minority of patients with chronic myeloid leukemia (73). This was somewhat 
surprising as early studies showed beneficial effects of dasatinib in PH animal models, similar 
to the effects of imatinib (84). Follow-up studies stated that dasatinib alone does not induce PH 
but rats that first received dasatinib later developed aggravated PH if they were subjected to 
classical inducers of PH, such as hypoxia (41). Hence, dasatinib predisposes for PH which is 
induced by a second hit, not unlike the above discussed VEGF inhibitor Sugen, also initially 
hypothesized to be beneficial in PH pathogenesis. Imatinib has not been reported to induce PH 
when tested alongside dasatinib (41) and possibly this is because of the absence of Src-
inhibition.  
However, imatinib has been shown to be cardiotoxic, possibly mediated by inhibition of c-Abl. 
This is of course an important concern in PAH patients with risk of right heart failure (60). 
Theoretically this could be avoided by more specific therapy, but a more recent study calls for 
caution as the physiological cardiomyocyte adaptation to load-induced stress in the left 
ventricle has been reported to depend on PDGF receptor signaling (18). Nevertheless, as PDGF 
inhibition is believed to mediate the beneficial effects of imatinib in PAH patients, further 
insight into the role of this potent growth factor family and its role in PH is warranted.  
 
1.4 The platelet-derived growth factor family 
In 1974, Ross et al discovered that whole blood serum potently induced SMC proliferation and 
that platelet depletion drastically reduced this effect, concluding there must be a platelet-
derived factor that stimulates SMCs growth (91). Others found platelet extract to also induce 
cell proliferation in fibroblasts, and in 1982 human PDGF-A and -B were separated (55) and 
subsequently characterized, as reviewed by Heldin and Westermark (47). It was not until the 
beginning of the 21st century that the other two ligands PDGF-C and -D were discovered (7, 
63, 67). To our current knowledge, the PDGF family consists of four ligands, PDGF-A through 
-D, that signals through the two tyrosine kinase receptors, PDGF receptor a (PDGFRa) and 
PDGF receptor b (PDGFRb).  
PDGF signaling primarily mediates cell proliferation, migration, and survival. The PDGF 
family belongs to the VEGF super family in which all ligands share a conserved growth factor 
domain (47). Further structural similarities are found in several VEGFs as well as in PDGF-A 
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and -B, as these ligands have a C-terminal retention motif that binds to extracellular matrix 
(ECM). This is of crucial importance for growth factor/morphogen gradients during 
development. Alternative splicing and posttranslational processing can however remove this 
retention motif, rendering the molecule more freely diffusible in the extracellular space (3). 
PDGF-C and -D lack retention motif but have an N-terminal domain, denominated the 
Complement subcomponents C1r/C1s, Urchin EGF-like protein, Bone morphogenic (CUB) 
domain, hypothesized to facilitate ECM interactions (3, 10). However, the CUB-domain in 
both PDGF-C and PDGF-D also blocks the receptor binding sites located in the growth factor 
domain. Therefore the CUB-domain needs to be proteolytically removed by extracellular serine 
proteases such as tissue-type plasminogen activator (tPA) for PDGF-C and urokinase-type PA 
(uPA) or matriptase for PDGF-D (34, 112). This enables storage of inactive PDGF-C and -D 
in the extracellular space. In contrast to PDGF-C and –D, PDGF-A and -B are intracellularly 
activated and released as active growth factors. 
PDGF ligands primarily exist as homodimers, i.e. PDGF-AA. -BB, -CC, and -DD. As ligands 
bind to the cognate receptor, the receptor subunits dimerize, forming primarily PDGFR-aa or 
PDGFR-bb complexes. All ligands except PDGF-DD are capable of binding and activating 
PDGFR-aa, but only PDGF-BB and -DD have been shown to act on PDGFR-
bb (3). Homodimers of both ligands and receptors are by far the most common and well-
studied in development, but there are exceptions which could have implications in disease. The 
heterodimeric PDGFR-ab has been found in certain tumors and likely contributes to pro-
oncogenic signaling (27). Also, in human platelets PDGF-A and -B are known to 
heterodimerize. However, so far there is no known physiological or pathological role of PDGF-
AB and, apart from platelets, cells rarely co-express PDGF-A and -B (3). In vivo it is clear that 
PDGF-AA and -CC primarily signal through PDGFRaa, and PDGF-BB primarily through 
PDGFRbb (3). It is likely, however not yet clearly demonstrated in vivo, that PDGF-DD 
signals via PDGFRbb. In this thesis, ligands and receptors will be described as PDGF-A, -B, -
C, -D, and PDGFRa, PDGFRb respectively. 
The PDGF system has been extensively studied in development and an intricate spatiotemporal 
regulation of both ligands and receptors have been reported. Knock out studies of PDGFRa 
and PDGFRb show severe and distinctly different phenotypes in mice. PDGFRa and the 
ligands PDGF-A and -C are abundantly expressed and highly important in organogenesis 
overall. The expression pattern of PDGFRb and PDGF-B is primarily vascular and this 
signaling pathway has been shown to be of importance for blood vessel formation and 
maturation (3). Prior to paper III in this thesis, the role of PDGF-D had not been thoroughly 
investigated in development. 
In general, epithelial or endothelial cells express PDGF ligands and the cognate receptor is 
expressed by nearby cells of mesenchymal origin, as described below. Since PDGF-B and 
PDGF-D are central to this thesis, PDGFRb signaling will be emphasized.  
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1.4.1 PDGFRa signaling in physiology  
Deletion of PDGFRa (Pdgfra-/-) in mice leads to a severe phenotype including deranged 
formation of multiple organs (100). Lack of PDGF-A to some extent match this phenotype but 
to more completely phenocopy the Pdgfra-/- mice, regarding abnormalities in neural crest 
formation, kidney development and palate formation, a double knock out of both PDGF-A and 
-C is required (24, 105).  
Whereas the Pdgfc-/- mouse phenotype is background dependent, both Pdgfa-/- and Pdgfra-/- 
mice either die prenatally, due to the above mentioned defects in organogenesis, or die 
perinatally due to abnormalities in lung development (11). Recently, PDGF-A mediated 
PDGFRa signaling has been shown to specifically direct postnatal lung maturation, involving 
recruitment of pulmonary myofibroblasts to create the secondary septation of alveoli (38). In 
adult life, PDGFRa signaling is less active. However, it is expressed on platelets and is of 
importance in negative feedback regulation and decreased coagulation (115) 
 
1.4.2 PDGFRb signaling in physiology  
As mentioned above PDGFRb and PDGF-B are primarily expressed within the developing 
vasculature, well characterized by previous studies and reviewed by Andrae et al (3). PDGF-B 
is found in vascular ECs (68) and during angiogenesis the leading endothelial tip cell produces 
an increased amount of PDGF-B as it migrates distally (36). As discussed above, PDGF-B 
contains a retention motif that anchors the growth factor to the EC surface and in the 
surrounding matrix. PDGFRb-expressing perivascular mesenchymal cells, i.e. vascular SMCs 
and pericytes, are activated by PDGF-B to migrate and proliferate. These mural cells therefore 
follow the angiogenic sprout and closely adhere to the PDGF-B emitting ECs (3). Knock out 
studies of Pdgfrb-/- and Pdgfb-/- mice show in large parts similar phenotypes, including a drastic 
reduction in vascular SMCs and pericytes that are loosely attached to the underlying 
endothelium. Blood vessel integrity is compromised, leading to micro-vascular bleedings and 
edema throughout the embryo, likely contributing to the prenatal mortality (49). Although 
PDGF-B / PDGFRb mainly display this vascular ECs / mural cell expression pattern, it is not 
exclusive to the vasculature. For instance, PDGFRb signaling is required for correct neural 
crest formation, complementing but not overlapping with the above mentioned PDGFRa 
function. Pdgfrb-/- and Pdgfb-/- embryos also display cardiac abnormalities such as ventricular 
septal defects, atrioventricular valve dysplasia, hypoplasia of cardiomyocytes and cardiac 
nerves (114). There are a few examples of phenotypical characteristics in Pdgfrb-/- mice that 
are worse than in Pdgfb-/- mice, suggesting a role for PDGF-D in development. In skeletal 
muscle and adrenal glands PDGFRb expressing mesenchymal cells are for example present to 
a greater extent in Pdgfb-/- than in Pdgfrb-/- mice (49).  
Since perinatal mortality of the Pdgfrb-/- and Pdgfb-/- mice hampers further investigation of 
PDGF-B mediated PDGFRb signaling, a mouse strain with targeted deletion of the PDGF-B 
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retention motif (Pdgfbret/ret) was created in the laboratory of Prof Christer Betsholtz. The 
mutated PDGF-B, lacking the retention motif, still has the capacity to activate 
PDGFRb. However, due to the lack of extracellular retention (further discussed below) the 
growth factor is more freely diffusible. Thus, this is an informative model for studies of the 
role of PDGF-B / ECM interactions in development and disease. To some extent, the Pdgfbret/ret 
phenotype resembles the one seen in Pdgfrb-/- and Pdgfb-/- mice. Embryonically, milder 
bleedings and edema have been observed and in the microvasculature, pericyte coverage is 
decreased and the remaining pericytes are loosely attached (69). This, in combination with 
similar findings in mice with altered sulfation of ECM molecules (1), discussed below, have 
further strengthened the view that EC derived PDGF-B attracts PDGF receptor positive mural 
cells which migrate along a gradient of the growth factors (3). Further, Pdgfbret/ret mice have 
slightly dilated and stiffer aortas, with an increased collagen deposition and in skeletal muscle 
fewer capillaries are found. Coherent with the embryonic edema, capillaries in the CNS of 
Pdgfbret/ret mice are more leaky and the blood brain barrier is compromised (76). Further studies 
have demonstrated that vascular mural cells, i.e. pericytes in the capillaries, are needed to 
maintain blood vessel integrity (4, 28). Pdgfbret/ret mice also develop a cardiac phenotype, 
however contrary to the myocardial hypoplasia seen in the full knock outs, Pdgfbret/ret mice 
instead display left ventricular hypertrophy (76). Since the stroke volume is increased and the 
systemic blood pressure is unaltered, and given the already mentioned vascular abnormalities 
in Pdgfbret/ret mice, this has been interpreted as an adaptive response and not a primary cardiac 
effect due to altered PDGF-B signaling. Right ventricular function and size in Pdgfbret/ret mice 
had not been examined previously and this is somewhat addressed in paper II. Furthermore, 
prior to paper III included in this thesis, not much was known about the role of PDGF-D in 
development. Expressional data had found PDGF-D in cardiac, renal, and cerebellar tissues, 
but the findings had not been further validated. As PDGFRb is the known receptor for PDGF-
D we however hypothesized that the effect of PDGF-D ablation in Pdgfd-/- mice might be found 
within the vasculature, or secondary in surrounding tissue. In short, Pdgfd-/- mice were found 
to have small alterations in systemic blood pressure and a discrete pericyte attachment defect 
in cardiac capillaries. Other systemic blood vessels were however unaffected. This is more 
thoroughly discussed below. 
As is the case for PDGFRa signaling, also PDGFRb activity is markedly decreased in the adult 
physiological steady state. Some homeostatic effects can be assumed based on side effects 
when therapies that affect PDGF signaling are administered. A common side effect of imatinib 
treatment, described above to inhibit both PDGF receptors, is for example interstitial edema. 
In addition, a previous study has demonstrated how PDGFRb is required for maintained 
extracellular fluid pressure, most likely by ECM interactions (47, 89).  
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1.4.3 PDGF signaling in disease 
Upon injury or in various forms of pathology, the PDGF system is reactivated. One example 
of this is wound healing where PDGF ligands are deposited, in large parts from accumulated 
platelets, and act on residual SMCs and fibroblasts to proliferate and migrate. The activated 
cells also both produce ECM molecules and exert tensile forces on these, thereby contributing 
to wound closure (47). Locally administered PDGF-B can be safely used to aid in wound 
healing (54). Thus, PDGF activation can be favorable, however if excessive, PDGFs can surely 
do harm. Examples of this can be found in transgenic mouse models, in which overexpression 
of any PDGF ligand will mediate cell growth and fibrosis (3, 115). Furthermore, below is a 
short overview of disease groups in which aberrant PDGF signaling is implicated.  
Cancer. Albeit only reported in uncommon types of cancer, several activating mutations have 
been found in malignant cells of gastrointestinal stromal tumors, dermatofibrosarcoma 
protuberans, glioblastoma, and chronic myeloid leukemia (3). Mutations include gene 
amplification, point mutations, deletions and all lead to overly activated PDGFRa and/or 
PDGFRb signaling, but each single mutation is however very rare. Furthermore, it is likely that 
PDGF play important roles in tumor stroma formation. Overexpression of miscellaneous 
PDGF ligands have been found in many tumors and this has been shown to stimulate fibroblasts 
to produce a permissive ECM as well as to recruit SMCs and pericytes to complement the 
simultaneous VEGF mediated angiogenesis, reviewed in (90). Furthermore, PDGFRb 
signaling has been implicated in endothelial to mesenchymal transition, an important feature 
of epithelial-derived cancer metastasis (3) and possibly also of PAH (12). 
Fibrotic disease. As mentioned above, experimental overexpression of PDGF ligands mediate 
fibrosis. In concert with this, PDGF has frequently been found to be upregulated in different 
types of fibrotic disease in for example liver, skin, kidney, heart, and lung (46). Although both 
PDGFRa and PDGFRb signaling are involved in the pathogenesis of kidney fibrosis (9), 
Pdgfd-/- mice have been shown to be partially protected. This is further addressed in the 
discussion of paper III (14). Pulmonary fibrosis is characterized by proliferation and activation 
of myofibroblasts and ECM deposition in the lung parenchyma and, to some extent, in the 
vascular wall. PH is an additional complication to this severe disease. PDGF-A and -B are 
upregulated and receptor tyrosine kinase inhibition by imatinib is efficient in the mouse model 
of disease, but unfortunately insufficient to help patients with pulmonary fibrosis. However, 
broader tyrosine kinase inhibition has been shown to slow down disease progression (46).  
Atherosclerosis and restenosis. In contrast to the normal vascular wall that express only low 
amounts of PDGF, all four PDGF ligands are found at elevated levels in atherosclerosis. 
Further, all cells implicated in the pathogenesis have been shown to express PDGF of some 
type and both PDGFRa and PDGFRb are found in SMCs and macrophages of the 
atherosclerotic lesions (85). Primarily PDGFRb signaling has been shown to be involved in 
formation of the fibrous cap, rich in SMCs and ECM (3). Similar molecular processes of 
excessive healing are present in restenosis of the vessel wall, i.e. full or partial obliteration of 
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the lumen following vascular injury/intervention. PDGFRb signaling has been shown to 
activate SMCs also in this condition and both PDGF-B and -D have been found to be 
upregulated (17, 85). PDGF-B neutralizing aptamers, PDGFRb inhibitory antibodies, and 
PDGF receptor tyrosine kinase inhibitors such as imatinib have all been shown to reduce 
restenosis in animal models (46). However, there is presently no established anti-PDGF therapy 
in clinical use. 
 
1.4.4 PDGF in pulmonary hypertension 
PDGF ligands and receptors have been shown to be involved in human PAH pathogenesis as 
well as in animal models of the disease. In 1998, Humbert et al first reported increased PDGF 
in lungs from idiopathic PAH patients (52). PDGF-A mRNA was detected by qPCR and an 
antibody recognizing both PDGF-A and -B revealed presence of PDGF-ligands in PAH lungs. 
Subsequently, in 2003 Balasubramaniam et al found PDGFRa and PDGFRb upregulation in a 
surgical model of PAH in fetal lambs. Vascular remodeling and hemodynamics were improved 
by a selective PDGF-B inhibiting aptamer (6).  
As mentioned above, in 2005 Schermuly et al used imatinib to reverse PH in animal models. 
PDGF-A induced pulmonary arterial SMC proliferation, and PDGF-B even more so. Imatinib 
decreased the proliferative effect of both growth factors, suggesting that both PDGFRa and 
PDGFRb signaling induce SMC proliferation in vitro. In vivo however, only PDGFRb, and 
not PDGFRa, was upregulated and activated in PH. Imatinib treatment decreased PDGFRb 
expression and signaling in vivo. Further, PDGFRb was shown to be increased in lungs from 
patients with idiopathic PAH (93). Since imatinib was an already approved for clinical use, and 
relatively well-tolerated by chronic myeloid leukemia patients, these findings sparked 
significant interest. Alongside further characterization of PDGF-signaling in PAH (80), several 
successful case reports followed and clinical trials were commenced. Somewhat 
disappointingly, the IMPRES trial proved imatinib, as an add-on therapy, to be less effective 
than hoped, although significant effects were seen on hemodynamics and exercise capacity. 
Also, imatinib proved to be poorly tolerated because of side effects. Importantly, subdural 
hematomas occurred in about 4% of imatinib treated PAH patients (50). Subdural hematomas, 
or other hemorrhagic complications, have not been observed during imatinib treatment in 
chronic myeloid leukemia. Probably this complication arise due to the simultaneous anti-
coagulative therapy that PAH patients often receive. Another smaller European study of 
imatinib in PAH patients found the same incidence of subdural hematomas, but also showed 
that by adjusting the anticoagulant therapy patients could stay on imatinib and no further 
subdural hematomas occurred (101). Professor Humbert, who was the first to report elevated 
PDGF levels in PAH patients deemed imatinib treatment to be inefficient and risky in an 
editorial in 2013 (51).  
However, one can argue that because of the adverse events, investigation of more specific 
therapeutic targets are warranted and further insight into PDGF biology is of interest. PDGF 
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signaling is potent and very likely implicated in PAH pathogenesis. When interfering with 
potent signaling pathways proportional measures of caution must be taken. Clearly, receptor 
tyrosine kinase inhibition, such as with imatinib can cause harm and, as discussed above, yet 
more unspecific tyrosine kinase inhibitors like dasatinib have been shown to even cause PAH. 
Since PDGF-B mediated PDGFRb signaling has been shown in many previous studies to be 
involved in the pathogenesis of PAH, further understanding of this signaling pathway is of 
importance. Prior to paper IV included in this thesis, a potential role of PDGF-D in PAH had 
not been addressed. 
 
1.5 The vascular extracellular matrix 
All cells exist in a context, interacting not only with neighboring cells but also with the 
surrounding ECM. In addition to providing a scaffold for cells, the ECM has active roles in 
regulating cell function.  
The vascular wall is composed of three layers; intima, media, and adventitia. The thickness and 
composition of each layer depends on the size and type of vessel, however healthy vessels share 
common characteristics. The luminal layer, the intima, consists of ECs which sit on a basement 
membrane, a specialized form of ECM. In capillaries there is no true media, but pericytes 
surrounded by a basement membrane, which they share with the adjacent ECs, partly cover the 
vessels. What is unique in pulmonary capillaries is that the endothelial ECM is shared with that 
of the alveolar epithelial cells, a basement membrane which needs to permit efficient diffusion 
of gases. In arterioles and arteries, the media is built up mainly of SMCs that surround 
themselves with a distinct type of basement membrane (45). The medial ECM also contains a 
variable amount of elastic fibers depending on the size of the artery. Further, small amounts of 
interstitial matrix like fibronectin, hyaluronic acid and proteoglycans, like versican, are present 
in the healthy vessel. The interstitial ECM components often increase in amount in pathological 
states. Continuing towards the abluminal side, the adventitia is more cell scarce. Adventitial 
fibroblasts produce fibrillar collagens (type I and III), providing tensile strength, and to some 
extent elastic fibers, however less organized compared to the elastic fibers in the media. 
The basement membrane is a specialized form of ECM, situated underneath ECs and 
surrounding pericytes and SMCs. It is mainly composed of network-forming collagen and 
laminin that are linked together by nidogen and perlecan (64). A majority of the basement 
membrane consists of collagen IV. Six distinct genes encode for six different collagen IV 
isoforms, all of which self-assemble into networks crucial for basement membrane stability. In 
mammals collagen IV genes are highly conserved, indicating their key role in basal biology 
(64). Next to collagen IV, laminins make up a large part of the basement membrane. 15 genes 
encode different laminin a, b, and g chains that are assembled into cross-shaped heterotrimeric 
molecules and subsequently into networks. Laminins are the matrix molecules that account for 
the major part of basement membrane heterogeneity in different vascular beds (42). Apart from 
binding to other ECM molecules, laminins directly induce signaling in primarily ECs, and to 
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some extent also in pericytes and SMCs, through membrane-anchored integrins, acting as 
laminin receptors (42, 120). The two glycoproteins nidogen 1 and 2 seem to have overlapping 
roles, namely stabilizing the basement membrane linking laminin and collagen IV networks 
(120). Perlecan is a large HS proteoglycan with binding sites for collagen IV, laminin, nidogen, 
hence anchoring the above mentioned structures to one another (64). However, perlecan has 
many diverse functions (72) and will be more thoroughly described and discussed below. 
 
1.5.1 Glycosaminoglycans and proteoglycans 
Glycosaminoglycans (GAGs) are negatively charged polysaccharide chains, including 
chondroitin sulfate (CS), dermatan sulfate (DS), keratan sulfate (KS), and heparan sulfate (HS). 
These sugar chains are covalently bound to a core protein, thereby forming a proteoglycan. 
Proteoglycans are classified according to the bound GAG chain, as discussed below, but many 
core proteins are capable of binding several different GAG chains. Further adding to the 
complexity, GAG chains themselves display a huge variation in composition and length. 
Hyaluronan, the only GAG chain that is not bound to a core protein, instead itself forms a 
macromolecule capable of attracting multiple other proteoglycans. The strong negative charge 
of many GAGs, and thereby proteoglycans, attracts cations, such as Na+, that are osmotically 
active. Hence, GAG rich tissue is spacious and gel-like in its nature (118).  
Of the CS proteoglycans (CSPGs), versican is believed to be the dominant one within the 
vascular wall. It has been shown to accumulate in systemic vascular disease (118) as well as in 
PAH (16). Cells can produce four different versican isoforms, V0 – V3, by alternative splicing 
of the the GAG binding domains. In both development and disease, versican and hyaluronan 
accumulate and bind, forming large pericellular aggregates that promote proliferation and 
migration (31, 117). However, biological actions of the versican isoforms differ and V3, which 
lacks GAG binding domains and therefore technically is no proteoglycan, has been shown to 
instead enhance a differentiated phenotype in cells (57). Other CSPGs of the vascular wall 
include decorin and biglycan, that both can bind DS interchangeably to CS. Decorin has been 
well studied in angiogenesis and has also been shown to inhibit transforming growth factor b 
in models of fibrosis. Biglycan has been found in atherosclerotic plaques and has been shown 
to contribute to lipid retention in the vascular wall (118). 
The syndecan family, syndecan-1, -2, -3, -4, all have a core protein anchored to the cellular 
membrane. They are primarily regarded as HS proteoglycans (HSPGs) but can also carry CS 
chains. Syndecan-1 have been shown to inhibit PDGF-B mediated SMC proliferation (13) 
while syndecan-4 can mediate PDGF signaling, as is known as a co-receptor to FGF receptor 
1 (FGFR1), thereby facilitating SMC proliferation (29). An important biological function of 
syndecans is shedding of the extracellular domains along with bound growth factors, which in 
part could explain contradictory reports and allows for finetuning of the signaling system. 
Glypicans are yet another class of cell surface HSPGs that can modulate signaling of growth 
factors such as FGFs (71). There is some redundancy in the HSPG system as exemplified by 
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that FGF2 signaling primarily is syndecan-1 dependent, but after syndecan depletion glypicans 
take over this role (25, 30). 
Perlecan is the major ECM HSPG of the vascular wall and, as mentioned above, a key 
component in the basement membrane. The perlecan core protein is large in size and consists 
of five distinct domains with three HS chains attached to the N-terminal domain I and one HS 
chain attached to the C-terminal domain V, also known as endorepellin (40). Variations in the 
perlecan macromolecule are numerous and takes place both on the posttranscriptional level and 
differently modified HS chains (62). Adding to the complexity, although perlecan is regarded 
primarily as a HSPG it can also bind CS chains (97). Depending on its structure and context, 
perlecan can take on different roles. For example, the full perlecan molecule has been found to 
promote angiogenesis, thought to be mediated by domain I HS creating growth factor gradients 
and facilitating formation of ligand-receptor complexes (123). Endorepellin alone, derived 
from either alternative splicing or proteolytic cleavage, instead inhibits angiogenesis (26), thus 
allowing for a negative feedback mechanism within the same molecule.  
In development, correct spatiotemporal coordination of morphogens and growth factors is of 
absolute necessity, and HSPGs have been found to regulate a majority of these factors. A well 
characterized example of this is found in neuronal axonal guidance where morphogens like 
Netrins, Slits, and Ephrins strongly bind to HS and alteration or depletion of HS result in axons 
not reaching their intended target (82). In the vasculature, growth factors such as VEGFs and 
PDGFs direct EC and mural cell propagation in a process very much dependent on that the 
extracellular growth factor gradient is maintained. Proper N-sulfation is required for efficient 
binding of PDGF-B to HS, via the retention motif, and interference with this interaction results 
in in altered growth factor signaling and a pericyte deficiency (1). Genetically modified mice 
(Hspg2r3/r3 mice) lacking the HS binding sites of perlecan domain I, have been shown to have 
significantly lower levels of overall HS in the vessel wall (110) and characterization of these 
mice revealed FGF2-induced corneal angiogenesis to be reduced (122). Further, perlecan play 
important roles in vascular remodeling as it has been shown to be upregulated early after 
systemic vascular injury (61). Hspg2r3/r3 mice subjected to vascular injury developed 
aggravated SMC rich lesions (110). Presumably this is due to loss of the otherwise protective 
role perlecan HS exert by sequestering growth factors, preventing receptor activation (40).  
 
1.5.2 Extracellular matrix in pulmonary hypertension 
The healthy pulmonary vascular ECM is elastic and permitting to the pulse wave, as the 
pulmonary circulation is a high flow, low resistance system. During steady state the matrix 
turnover is low, but in vascular disease ECM remodeling plays a pivotal role. In principle, 
vascular ECM remodeling in PAH can be divided into three different categories, as described 
below. 
Proximal pulmonary artery stiffening. In PAH, fibrous collagens are increasingly deposited 
and cross-linked in the proximal pulmonary artery. In parallel, elastin is degraded and leads to 
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loss of compliance and stiffening of the vascular wall. This can be closely examined in animal 
models (8) and can be visualized by magnetic resonance imaging (92). The hemodynamic 
implications of the proximal pulmonary arterial stiffening are apparent in routine 
echocardiography in PAH patients.  
Muscularization of intra-acinar arterioles. In the more distal pulmonary vasculature, the ECM 
of pre-capillary vessels consists only of a thin basement membrane underneath the endothelial 
layer in the healthy lung. In PAH patients and in animal models, ECM turnover is increased 
and proteoglycans accumulate in in the vessel wall (16, 70). This newly formed, or transformed 
matrix, is permissive to cell migration and induces cell proliferation. In the quiescent state 
proteoglycans can sequester growth factors, withholding them from their cognate receptors. 
However, in vascular remodeling these pooled growth factors may be released by proteolytical 
cleavage. One example of this is shown in SMCs that secrete serine elastases that act on 
surrounding matrix to release FGF2, thus inducing cellular proliferation and migration (109). 
Proteoglycans constitute the group of matrix components which most clearly accumulates in 
the early phase of disease (118). The role of proteoglycans and growth factor – matrix 
interactions in remodeling of intra-acinar vessels is one of the main topics of this thesis and is 
thoroughly discussed in other sections. 
End-stage obliterative lesions. Increased muscularization of intra-acinar arterioles is 
unfortunately the only feature of PAH vascular remodeling which can be studied adequately in 
the mouse hypoxia model. However, in human disease neointima formation and plexiform 
lesions are important components of the pathology. When studying advanced vascular lesions 
it is very clear that some are highly cellular while others contain primarily ECM. In 1958 when 
Heath and Edwards classified PAH histopathology into 6 different grades with increasing 
severity they suggested that the intimal reaction gradually evolves from cellular to fibrous and 
fibroelastic (44). However, other factors than age of the lesion may affect composition. 
Positioning within the pulmonary vascular tree may for example be an important factor. 
By whole-exome sequencing, the versican gene is shown to be one of the most frequently 
mutated genes in PAH patients (23) and abundant amounts of versican was found in both 
medial hypertrophy and plexiform lesions in PAH vasculature (16). As discussed above, 
hyaluronan is often co-localized to versican, forming a provisional pro-migratory/proliferative 
matrix. Coherently, hyaluronan is also found in PAH vascular lesions (5). Noteworthy, PDGF 
has been shown to stimulate pulmonary arterial SMCs to form pericellular versican-hyaluronan 
aggregates (31). Several other proteins, like tenascin C and fibronectin, have also been shown 
to accumulate in advanced lesions (56). Growth factor gradients and other types of interactions 
between the ECM and growth factors and cytokines, as well as active proteolytic ECM 
turnover, are likely to be of crucial importance also in advanced human PAH. Those 
mechanisms were unfortunately not possible to address adequately in this thesis because of the 
limitations of the model used.  
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1.6 microRNA in pulmonary hypertension 
As discussed above, numerous proteins have been studied and found to be implicated in PAH 
pathobiology. Protein composition, amount, spatiotemporal accumulation etc, are dependent 
on many factors. One is of course gene expression and further translation. This process is 
highly regulated by non-coding RNAs, a group of molecules that in recent years have 
received increased attention and have been found to direct several pathological processes (2). 
One type on non-coding RNAs are the microRNAs (miRNAs), shown to have potent 
inhibitory effects by either mediating messenger RNA (mRNA) degradation or by inhibiting 
mRNA translation. Typically, one miRNA has many targets and several different miRNAs 
often target the same mRNA, indicating a redundancy that allows for fine tuning of the 
system. Over the past decade, an increasing number of miRNAs have been investigated in 
PAH. Caruso et al presented a nice overview of how miRNAs are differentially expressed 
over time in the mouse hypoxia and the rat monocrotaline model of PH (15). Current 
knowledge of miRNAs in PAH was recently reviewed by Negi and Chan, where the authors 
summarize implicated miRNAs, their targets, and future perspectives of miRNA based 
therapy or diagnostics of PAH (75). Several, if not all, PAH signaling pathways are subject to 
miRNA control. One rather well studied example is the BMPR2 pathway, in which signaling 
activity is reduced in many genetic and environmental forms of PH in patients and animal 
models (108). Several miRNAs have been shown to target Bmpr2 mRNA and some of these 
are upregulated in PH, one of the better characterized being miR-21 (75). Inhibition of miR-
21 has been shown to attenuate hypoxia-induced PH in mice, but the authors found no 
profound effects in levels of miR-21 targets and conclude this to likely be due to the many 
shared targets of miRNAs (119). Likely because of redundancy and overlapping microRNA 
effects, inhibiting one miRNA has, so far, not yielded great treatment success in animal 
studies and to apply a miRNA based therapy in humans may lead to many off-target effects 
(75). However, miRNA analyses could reveal new and unexpected therapeutic targets for 
future PAH therapy, or function as diagnostic tests in patients. In paper IV, a miRNA array 
was used to broaden the search for possible alterations of importance to PH development in 
Pdgfd-/- mice.  
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2 Animal models of PH – strengths and limitations 
This thesis work is primarily based on studies of genetically modified mice that were 
investigated in the hypoxia model of PH. Mice were kept in 10% oxygen, equivalent to 6000 
meters above sea level, during 4 weeks. Following chronic hypoxia, vascular and 
hemodynamic parameters were subsequently assessed. In this section, the applied method is 
discussed in the context of limitations and other possibilities. 
Acute hypoxia-induced PH was first demonstrated in 1946 by researchers at the Karolinska 
Institute. By catheter, the pulmonary arterial pressure was obtained in anesthetized cats and 
results showed hypoxia to directly induce pulmonary vasoconstriction, later known as the 
Euler-Liljestrand mechanism (98). In physiologic conditions, pulmonary vasoconstriction 
regulates shunting of blood from less oxygenated lung segments towards better ventilated parts, 
thereby bringing balance between ventilation and perfusion. However, if all airways are 
hypoxic, global pulmonary vasoconstriction will occur and thus PVR and pulmonary arterial 
pressures will rise. Over time, chronic hypoxia due to high altitude or pulmonary disease, is a 
risk factor for manifest PH in humans as pulmonary vascular remodeling may occur (108). In 
part, this is dependent on hypoxia-induced signaling pathways and also thought to be 
exaggerated by increased shear stress acting on the ECs.  
Similar to the human situation, chronic hypoxia can lead to chronic PH in animals, although to 
a varying degree in different species. Cattle are more prone to hypoxia-induced PH than sheep 
and rats are more sensitive than mice (37). In the experimental PH setting, larger animals are 
used to some extent. However, the majority of research is performed in rodent models. The 
possibility to genetically modify mice has played a pivotal role in understanding basic biology. 
Subsequently, to challenge mice in disease models have led to groundbreaking revelations of 
pathobiology, although not without trouble with low translational success, in large part thought 
to depend on differences between human and murine disease (37). Clearly, the major advantage 
of utilizing the chronic hypoxia mouse model is the feasibility to investigate specific molecular 
alterations.  
The pulmonary vascular pathology of hypoxia-treated mice primarily consists of distal 
muscularization of previously non-muscularized small pulmonary vessels, by accumulation of 
SMC-like cells. Further, media hypertrophy, adventitial fibrosis and to some extent 
perivascular inflammation are present (104). However, as opposed to human PAH, no neo-
intima formation and no plexiform lesions are found in hypoxia-treated mice. Coherent to the 
mild vascular disease, right ventricular systolic pressure (RVSP) elevation and right ventricular 
hypertrophy is mild, but consistent, and the parameters display a high reproducibility. In 
attempts to better mimic the human situation various strategies have been tested, several of 
which have been found to work only in rats and not mice. In general, the rat pulmonary 
vasculature is more responsive and mice are more resistant. This is the case also for the VEGF-
inhibitor Sugen, discussed in the introduction. In rats, VEGF inhibition predisposes for 
aggravated PAH when animals are later exposed to chronic hypoxia. Rats only subjected to 
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hypoxia fully recover if they are again housed under normal circumstances, while rats that also 
received Sugen treatment continue to deteriorate even after returning to normoxia, thus better 
recapitulating human disease. In mice, there are somewhat contradictory reports, as some 
research groups report Sugen-hypoxia to induce profound PH with plexiform-like vascular 
lesions and worsened hemodynamic parameters (19), while others found more modest effects 
and, importantly, a spontaneous regression of disease when mice are returned to normoxia 
(116).  
Another example of successful induction of disease in rats but not mice is the long used 
monocrotaline model, first reported to induce PH in laboratory rats 50 years ago (59). 
Monocrotaline is a toxic plant-derived alkaloid, that when ingested is activated in the liver and 
thereafter causes vascular injury. Contrary to rats, mice lack the relevant enzymes and do not 
reliably develop PH (37). As the pulmonary circulation ensues that of the liver vascular injury 
is concentrated there and severe PH arises. This is among the more severe models of disease 
and is eventually lethal due to RV failure. However, endothelial damage is not exclusive to the 
pulmonary arterioles. Monocrotaline reliably produces hepatic veno-occlusive disease, and 
cause significant hepatic and kidney damage as well as myocarditis. Monocrotaline mediates 
acute toxicity and the relevance for human disease and thus therapeutic development is debated 
(104).  
In the subgroup of PAH associated with congenital heart defects, increased pulmonary blood 
flow due to systemic-to-pulmonary shunts, is common. Patients develop obliterative vascular 
lesions, as in other PAH groups, and this is thought to at least in part be induced by the increase 
of shear stress on the vascular wall. Several surgical models in larger animals cause increased 
flow and PAH (21, 86). In rats this has been investigated in the monocrotaline model which 
has been combined with both pneumectomy (producing a doubling of blood flow to the 
remaining lung) and later with a less traumatic aorto-caval shunt that induce volume but not 
pressure overload of the pulmonary circulation. Both pneumonectomy and aortocaval shunt 
operation aggravates the monocrotaline model, giving rise to more severe obliterative vascular 
lesions and worsened hemodynamics (104, 113).  
In mice the above mentioned surgical techniques are less well tolerated and models of PAH 
associated with congenital heart disease are yet to be established. Instead, as already mentioned, 
the possibility of altering the mouse genome is the great advantage of this model and indeed, 
knock out or overexpression of certain genes are found to cause disease more like what is found 
in PAH patients. Further, genetic mutations found in patients can be reproduced and tested in 
the mouse model. Such is the case for BMPR2 which is the most common loss-of-function 
mutation in both hereditary and sporadic PAH, as mentioned in the introduction. Coherently, 
heterozygous knock out of the Bmpr2 gene gives rise to mild PAH that is aggravated by chronic 
hypoxia (33). Similarly, although no genetic mutation has been found in PAH patients, IL-6 
levels are elevated and transgenic overexpression of Il6 in mice that are subjected to hypoxia 
gives rise to severe PH (43, 103). Further, as discussed above, PDGFRb and PDGF-B are 
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increased in PAH patients and implicated in pathogenesis, hence this is the rationale for using 
genetically modified mice in this thesis work.  
In summary, hypoxia induces mild PH in mice. However the pathology is consistent and 
display the least variation of the described models. Certain features are similar to human disease 
while many are not. Obviously, this is mandatory to consider when interpreting or even 
extrapolating findings from mouse studies. It is well acknowledged that many agents effective 
in animal models have been proven ineffective, or even harmful, in patients (108). Indeed, this 
problem of low translational success is not exclusive to the PAH field but is an inherent part of 
medical research (79, 83). To a large part, this is due to dissimilarities between available animal 
models and human disease. Further, considering the dissimilarities to human PAH, it is not 
clear which approach should be depicted a PAH or PH model, and in the literature these are 
used interchangeably.  
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3 Aims of the thesis 
Current PAH therapy is focused on vasoconstriction and has significant, yet unsatisfactory, 
effects on survival and quality of life. PAH research is therefore largely focused on elucidating 
remodeling processes, addressing the involved signaling pathways leading to the proliferative 
and migratory cell phenotypes which contribute to pulmonary vascular lesions.  
As the title of this PhD thesis implies, Pulmonary Hypertension – The Role and Place of PDGF, 
we aimed to explore ECM – growth factor interactions in PH pathobiology, focusing on spatial 
distribution of PDGF. Furthermore, the relatively newly discovered PDGF family member, 
PDGF-D, has been characterized and a potential role in PH has been investigated.  
 
Specific aims include: 
Paper I 
To investigate the role of extracellular perlecan HS in hypoxia-induced PH. 
Paper II 
To further explore the role of PDGF-B in PH, focusing on the role of the retention motif in 
pulmonary vascular remodeling. 
Paper III  
To examine the biological function of PDGF-D and thoroughly characterize the Pdgfd-/- mouse 
under normal conditions. 
Paper IV  
To investigate the role of PDGF-D in pulmonary vascular remodeling and to test the effects of 
genetic PDGF-D ablation in the chronic hypoxia model of PH. 
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4 Results and discussion 
4.1 PAPER I  
Perlecan Heparan Sulfate Deficiency Impairs Pulmonary Vascular 
Development and Attenuates Hypoxic Pulmonary Hypertension 
In paper I, the role of perlecan HS in hypoxia-induced PH was investigated. Perlecan is the 
largest and most abundant HSPG in the vascular wall ECM. Its biological function vary 
depending on setting and on which part of the molecule is examined, and indeed perlecan has 
been denominated “the jack of all trades” (40, 72). The full perlecan molecule facilitates 
angiogenesis (123) whereas, after proteolytic cleavage, the c-terminus derived endorepellin 
inhibits angiogenesis (26). The perlecan core protein contains several binding sites for 
negatively charged HS chains, which in turn bind a variety of positively charged growth factors, 
such as VEGF, FGF, and PDGF (40). The ECM-growth factor binding can both sequester 
growth factors or present them to their cognate receptors, as is exemplified in FGF2 signaling 
(97).  
Our group previously found perlecan HS to protect against intimal hyperplasia and excessive 
SMC proliferation in the systemic circulation (110, 111). The initial hypothesis for paper I was 
that this observation would be true also in the pulmonary circulation and that genetically 
modified mice lacking the major HS binding sites of the perlecan core protein (Hspg2r3/r3 
mice) would develop aggravated PH following hypoxia. However, this was not the case. 
Firstly, baseline normoxia characteristics revealed Hspg2r3/r3 pulmonary intra-acinar vessels 
to have a significantly lower proportion of SMC and pericyte coverage compared to wild type 
(wt) controls. Pulmonary angiography then revealed a marked arborization defect. However, 
hemodynamic parameters were unchanged in Hspg2r3/r3 mice in normoxia, suggesting a PVR 
corresponding to that of wt controls. Hence, the pulmonary arterial compliance is probably 
increased in Hspg2r3/r3 mice, a parameter shown to decrease in PAH and predict severity of 
disease (8, 92). As shown in other vascular diseases, remodeling of the otherwise dormant and 
stable ECM is initiated and, early in the process, proteoglycans make up for the majority of the 
deposited ECM molecules (118). Indeed, in paper I, an increase of perlecan gene expression 
was found early in hypoxia and later there was a clear accumulation of perlecan protein in the 
vascular basement membrane. Hence, perlecan could play a similar role in pulmonary vessels 
as in systemic vascular remodeling, where perlecan is also upregulated (61) and loss of perlecan 
HS has been shown to worsen disease. Contrary though, hypoxia-induced pulmonary vascular 
remodeling was significantly attenuated in the Hspg2r3/r3 mice. In line with a less affected 
remodeling, also the hypoxia-induced RVSP increase and right ventricular hypertrophy were 
attenuated in the Hspg2r3/r3 mice compared to wt controls. In summary, depletion of perlecan 
HS led to partial protection against hypoxia-induced PH.  
Further characterization of the vascular phenotype revealed lower FGF2 levels in Hspg2r3/r3 
mice than in wt controls, following chronic hypoxia. Interestingly, also the formation of 
perlecan/FGF2/FGFR1 complexes and FGFR1 activation were drastically decreased in 
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Hspg2r3/r3 mice. This indicates a role for perlecan HS in ligand-receptor presentation in 
pulmonary vascular remodeling, as has previously been reported in the systemic circulation 
(97).  
The combination of decreased FGF2 signaling and ameliorated hypoxia-induced PH in 
Hspg2r3/r3 mice is intriguing. FGF2 has been found to be upregulated in idiopathic PAH 
patients and inhibition of this pathway reverses experimental PH (53). In a more recent 
publication Ricard et al found FGF2, together with IL-6, to drive pericyte proliferation and 
migration thus giving rise to SMC-like cells in vascular remodeling of PH (87). Indeed, in 
paper I, Hspg2r3/r3 mice did have fewer pericytes at baseline. It would be interesting to closer 
analyze the pericyte phenotype also after hypoxia-treatment. In paper II, this analysis was 
performed and revealed a similar pericyte phenotype in mice devoid of the PDGF-B retention 
motif. To note, we did not find any significant alterations in PDGF-B mRNA levels following 
hypoxia and neither did Ricard et al in the above-mentioned study. However as the authors 
conclude, this could be due to other control mechanisms than mere gene expression, such as 
extracellular sequestration and proteolytic release of PDGF-B. PDGF-B signaling has been 
thoroughly studied and found to regulate both SMC and pericyte fate in multiple organs (3, 49, 
69), including the pulmonary vasculature in PH development (93, 94). Additionally, the PDGF-
B molecule contains a retention-motif that strongly binds to extracellular proteoglycans, 
investigated in paper II.  
To summarize, our findings in paper I partly cohere with, as well as divert from, previous 
studies. A vascular arborization defect has not previously been reported in unchallenged 
Hspg2r3/r3 mice. However, it does resemble the findings of impaired FGF2-driven 
angiogenesis in Hspg2r3/r3 mice (122). Also, this is in line with the perlecan-mediated 
regulation of VEGF-induced angiogenesis during development, thought to depend on an 
ordered growth factor gradient in the HS-rich ECM (123). The spatiotemporal signaling is 
crucial for the biological action of a multitude of growth factors, and there is a possible 
derangement in this process for many more factors than FGF2 in the Hspg2r3/r3 mice. 
 
4.2 PAPER II  
Extracellular Retention of PDGF-B Directs Vascular Remodeling in Mouse 
Hypoxia-induced Pulmonary Hypertension  
PDGF-B mediated PDGFRb signaling has been extensively studied in PH and the cancer 
therapeutic agent imatinib has been shown to reverse experimental PH and is thought to do so 
mainly by PDGF receptor inhibition (93). However, subsequent clinical trials reported a high 
discontinuation rate and serious adverse events in imatinib treated PAH patients (35, 50, 101). 
However, as discussed in the introduction, imatinib is not a specific inhibitor of the PDGF 
receptors and indeed targets several tyrosine kinase receptors. In paper II, we aimed to further 
elucidate the role of PDGF-B in PH and highlight the importance of growth factor-ECM 
interactions. 
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As described in the introduction, the PDGF-B molecule contains a retention motif, a cluster of 
positively charged amino-acids, proposed to bind to negatively charged proteoglycans by the 
cell surface and in the ECM (3). Genetically modified mice devoid of the PDGF-B retention 
motif (Pdgfbret/ret mice) display detached pericytes and leaky blood vessels in the systemic 
circulation, most probably due to a deranged extracellular gradient of the growth factor (69). 
Interestingly, a similar phenotype is evoked by reduced N-sulfation of HS in mice (1). The role 
of PDGF-B retention had until this present study not been investigated in PH. 
Besides the already reported left ventricular hypertrophy in Pdgfbret/ret mice (69), we found a 
corresponding and balanced RV hypertrophy, resulting in a normal Fulton ratio (RV/(left 
ventricle+septum) dry weight). As with the systemic blood pressure (69) normal RVSP was 
found in Pdgfbret/ret mice at baseline in normoxia. Further, there were no apparent differences 
in gross lung morphology or intra-acinar vessels in Pdgfbret/ret mice. 
When challenged with chronic hypoxia, Pdgfbret/ret mice displayed unaltered hemodynamic 
parameters and seemed protected against developing PH. We therefore expected to find 
markedly less vascular remodeling. However, the initial morphometric analysis revealed a 
hypoxia-induced vascular remodeling which was close to that found in control mice. Although 
mouse models of PH are known to sometimes not cohere in vascular remodeling and 
hemodynamic measurements (37), this complete uncoupling prompted a closer examination 
that revealed a deranged muscularization of intra-acinar vessels in Pdgfbret/ret lungs. SMC-like 
cells were found detached from the normally muscularized intra-acinar vessels, not unlike the 
previously discussed pericyte phenotype in the same mouse strain (69). Closer characterization 
of the scattered SMC-like cells revealed a very high co-expression of smooth muscle myosin 
heavy chain (SMMHC) with alpha smooth muscle actin (aSMA), suggesting a SMC origin as 
SMMHC is previously shown to distinguish between mature SMCs and other vascular mural 
cells (77, 121). However, a minority of the aSMA positive, SMC-like cells, also expressed the 
pericyte marker neural glial antigen-2 (NG2), and indeed we cannot rule out the possibility that 
those cells are of pericyte origin.  
The importance of spatiotemporal PDGF-B / PDGFRb signaling was recently demonstrated 
by Sheikh et al (94). PDGF-B was shown to first be upregulated globally and then polarizing 
distally in the lung, acting as a pro-migratory factor for PDGFRb positive SMCs. This is very 
much in line with our current view and the findings in paper II. Our hypothesis is that a hypoxia-
induced increase of PDGF-B leads to a deranged extracellular PDGF-B gradient in Pdgfbret/ret 
mice, resulting in PDGFRb positive cells detaching from the intra-acinar vessels. Due to lack 
of time points and fate mapping of cells in the studied model, we have so far not been able to 
make a final conclusion on the origin of the disorganized SMC-like cells in Pdgfbret/ret mice. 
As mentioned above, we found the pericyte marker NG2 in some of aSMA positive cells. A 
prior study by Ricard et al (87) found that FGF2 and IL-6 can drive pericyte proliferation, 
migration and differentiation into SMC-like cells, thereby contributing to hypoxia-induced 
vascular remodeling. In our current study, a marked increase of Il6, but not Fgf2, transcription 
was found in Pdgfbret/ret lungs after four weeks of chronic hypoxia. This indicates a possible 
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ongoing vascular remodeling in Pdgfbret/ret mice, which coheres well with the observed increase 
of Acta2 mRNA (translating into αSMA protein), which was not seen in control mice after 
completed hypoxia treatment. Accumulation of αSMA protein was however equally high in 
controls as in Pdgfbret/ret mice following hypoxia. Furthermore, since pericyte deficiency can 
lead to abnormal angiogenesis (48) and vessel loss (121) pulmonary intra-acinar vascular 
density was investigated, but no significant differences were found in Pdgfbret/ret mice.  
In summary, the results of paper II point to the importance of extracellular binding of PDGF-
B. Removal of the PDGF-B retention motif gives rises to a more freely soluble molecule and 
hence, the migratory gradient is deranged. The signaling properties are however preserved in 
the mutant PDGF-B protein, as shown by a prominent hypoxia-induced vascular remodeling 
in Pdgfbret/ret lungs. Although prominent, this disorganized muscularization of intra-acinar 
vessels gives rise to a dysfunctional SMC layer unable to constrict the pulmonary vessel lumen, 
protecting Pdgfbret/ret mice against hypoxia-induced PH. 
 
4.3 Paper III  
Mice Lacking Platelet-Derived Growth Factor D Display a Mild Vascular 
Phenotype 
As discussed in the introduction, the PDGF family consists of four ligands, PDGF-A through 
-D, that act on the two tyrosine kinase receptors PDGFRa and PDGFRb. Apart from PDGF-
D, the PDGF signaling system has been extensively studied and well characterized, in large 
part through studies of genetically modified mice. Prior to the current paper III, a genetic knock 
out mouse model of PDGF-D was not available. Earlier studies have however shown PDGF-
D, alongside PDGF-B, to potently activate PDGFRb. Genetic ablation of PDGFRb or PDGF-
B gives rise to very similar phenotypes, primarily including vascular abnormalities such as 
microvascular bleeding, leaky vessels and severe edema in the embryonic stage. One key 
attribute of both Pdgfrb-/- and Pdgfb-/- mice is considerably reduced vascular SMC and pericyte 
coverage (49). As there is a high consistency between the Pdgfrb-/- and Pdgfb-/- phenotypes, 
and since PDGF-D is only known to signal through PDGFRb, we anticipated the Pdgfd-/- 
phenotype to be more modest.  
In this study, a deficient PDGF-D mouse model was created and thoroughly investigated. 
Firstly, Pdgfd-/- mice were found to be viable and fertile and no apparent abnormalities were 
observed. Next, Pdgfd expression analysis was performed to identify high expressing organs 
as well as which cell types that produce PDGF-D. Gene expression was assessed quantitively 
by qPCR analysis and morphologically in heterozygotic Pdgfd+/- mice by taking advantage of 
the Lac-Z reporter gene, inserted in the deleted Pdgfd exon. Pdgfd expression was found in all 
organs investigated and mainly in the vasculature. Subsequent detailed expression analysis 
revealed Pdgfd to be predominantly expressed by vascular ECs and to some extent also by 
SMCs. Further, results pointed to a higher Pdgfd expression in arteries than in veins and the 
expression appeared to be concentrated to arterial bifurcations.  
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Given this vascular pattern and high Pdgfd expression in the heart, combined with previous 
results showing the importance of PDGFRb signaling for mural cells, pericyte coverage and 
vascular density was investigated in the myocardium of Pdgfd-/- mice. Indeed, pericytes 
appeared more detached and pericyte coverage was decreased in Pdgfd-/- mice, but the 
alterations were discrete. Correspondingly, qPCR of whole heart lysate revealed small but 
significant decreases of Cspg4 and Des, translating into the pericyte markers NG2 and desmin. 
Coherent with our interpretation of a mild pericyte phenotype, the cardiac microvascular 
density was unchanged and no vascular leakage was detected. Further, Pdgfd-/- hearts appeared 
normal in gross morphology and heart weight was unaltered. Pericyte detachment was only 
observed in the cardiac microvasculature. Hence, the pericyte phenotype in Pdgfd-/- mice was 
clearly not as severe as in Pdgfrb-/- and Pdgfb-/- mice, in which edema and microvascular 
bleedings contribute to embryonic lethality (68, 99). To investigate a possible physiological 
importance of the cardiac phenotype, systemic blood pressure was recorded and indeed a small, 
albeit statistically significant, elevation of systolic and diastolic blood pressure was found in 
Pdgfd-/- mice.  
Serum analyses revealed Pdgfd-/- males to have a minimal elevation of calcium (102% of 
control) and a slight decrease of chloride (97% of control). This was not observed in female 
mice and all other serum analyses (including liver enzymes, albumin, potassium, and sodium) 
were unaltered in Pdgfd-/- mice of both sexes. Further, blood glucose homeostasis was tested 
and found unaffected by PDGF-D ablation. 
In short, Pdgfd-/- mice displayed a number of discrete but statistically significant alterations. 
Most probably, these are of modest biological importance in the healthy situation since all of 
the alterations were small in magnitude and the general health of the Pdgfd-/- mice seems 
unaffected.  
Following this thorough characterization of the Pdgfd-/- mouse model it was possible and 
appealing to test potential effects of PDGF-D ablation in disease models. In a study of renal 
scarring, Pdgfd-/- mice were partially protected as they displayed an attenuated fibrotic 
response, likely due to an abrogated PDGF-D effect on fibroblast proliferation and ECM 
production (14). In yet another study, PDGF-D ablation was investigated in the RIP1-Tag2 
mouse model of pancreatic neuroendocrine tumors. Lack of PDGF-D led to a delayed tumor 
growth, however a compensatory upregulation of PDGF-B was discovered and Pdgfd-/- mice 
did eventually reach a similar tumor burden as controls (22). Interestingly, a specific 
subpopulation of PDGFRb positive cells was identified, responsive only to PDGF-D and not 
PDGF-B. This is indeed intriguing and allows for speculation that PDGF-D might have specific 
cellular effects, independent of PDGF-B. Possibly this is due to the recently reported co-
receptor to PDGFRb, namely neuropilin-1 which has been shown to facilitate receptor binding 
for PDGF-D but not PDGF-B (74). Interestingly, the same study also found the CUB-domain 
of PDGF-D to block heparin binding. Following proteolytic cleavage into its active form, 
PDGF-D was observed to bind heparin, thus opening for speculations on possible ECM or cell 
membrane retention.  
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4.4 Paper IV  
PDGF-D is a Potent but Redundant Mitogen in Pulmonary Hypertension  
PDGF-D had prior to this study not been investigated in PAH. Previous studies have shown 
PDGF-D upregulation in vascular remodeling in both a carotid injury and an atherosclerosis 
model (17, 58). Transgenic overexpression of PDGF-D in cardiomyocytes also potently 
induced vascular remodeling and SMC accumulation in nearby microvessels (81). This 
prompted us to challenge Pdgfd-/- mice in the hypoxia model of PH.  
Firstly, PDGF-D was demonstrated in patients with idiopathic PAH. Lung tissue was examined 
by immunohistochemistry and PDGF-D was found to be present in vascular lesions. PDGF-D-
staining localized to areas rich in SMCs and to some extent also to ECs. Next, as a proof of 
concept, the mitogenic capacity of PDGF-D was tested on human and mouse pulmonary 
arterial SMCs. Indeed, PDGF-D was found to induce proliferation at least as potently as PDGF-
B, which was used as a positive control. Given these initial findings and the previous 
knowledge of PDGFRβ in PAH, we hypothesized that PDGF-D could potentially drive PH 
development. If so, PDGF-D would be an attractive therapeutic target, considering the rather 
mild phenotype of genetic PDGF-D ablation described in paper III.  
Pdgfd-/- mice were exposed to chronic hypoxia, after which vascular remodeling and 
hemodynamic parameters were analyzed. Despite the observed mitogenic effect of PDGF-D 
on pulmonary SMCs, Pdgfd-/- mice displayed no significant alterations of intra-acinar vessel 
muscularization neither at baseline normoxia nor after chronic hypoxia. Pulmonary vascular 
remodeling in Pdgfd-/- mice was indistinguishable from wt controls. In line with these findings, 
RVSP and Fulton ratio was unaltered by PDGF-D ablation, both in normoxia and hypoxia. Of 
note, RVSP pressure recordings in Pdgfd-/- mice displayed a substantial variation, not seen in 
any other experimental group. However uncertain what this might stand for, a more thorough 
examination of the right ventricular and vascular remodeling in Pdgfd-/- mice would be of 
interest. Further, Pdgfd-/- mice had normal baseline Hb and a physiological hypoxia-induced 
increase of Hb, as did wt control mice.  
A previous study of the same mouse strain in a vascularized tumor model, found Pdgfd-/- mice 
to have elevated Pdgfb mRNA levels, possibly compensating for the lack of PDGF-D (22). To 
investigate whether Pdgfd-/- mice were subject to any such compensatory alterations in this 
present study, mRNA for PDGFRb and its other ligand PDGF-B was analyzed. After four 
weeks of hypoxia, no upregulation of Pdgfb was seen, regardless of genotype. Wt mice had an 
expected hypoxia-induced upregulation of Pdgfrb, however, this was absent in Pdgfd-/- mice. 
Similar results were found in another disease model of kidney fibrosis, where Pdgfd-/- mice 
displayed lower levels of both Pdgfb and Pdgfrb. However, in that model Pdgfd-/- mice were 
partially protected against disease and the lower amounts of Pdgfb and Pdgfrb could reflect a 
lesser fibrotic activity. In our current study, Pdgfd-/- mice were not protected against disease 
and we found no apparent morphological differences in vascular remodeling as compared to 
wt controls.  
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To widen the search for possible compensatory alterations in Pdgfd-/- mice, a miRNA array 
was performed. 84 miRNAs implicated in vascular disease were screened and subsequently 
validated. This screening confirmed a hypoxia-induced upregulation of miR-21 and miR-451 
in wt mice, as has been reported in previous studies (39, 119). miR-21 levels did not differ 
between genotypes. However, miR-451 was clearly lower in hypoxia-treated Pdgfd-/- mice than 
in wt controls. Possible targets of miR-451, that are also implicated in PAH, include mRNAs 
for several key components in IL-6 signaling. Although yet unconfirmed, it is tempting to 
speculate that hypoxia-induced upregulation of IL-6, IL-6 receptor and STAT-3 levels could 
be higher in Pdgfd-/- mice, secondary to an attenuated inhibitory effect of miR-451. 
Interestingly, IL-6 levels are increased in PAH patients and IL-6 receptor blockade is effective 
in preventing hypoxia-induced PH in mice (43). Further, transgenic IL-6 overexpression 
combined with chronic hypoxia, are among the most severe mouse models of PH (37, 103).  
Clearly, it would be interesting to follow up on the possibility of an accentuated IL-6 
component of PH development in Pdgfd-/- mice. Again on a speculative note, PDGF-D 
signaling could be directly required for the hypoxia-induced upregulation of miR-451 seen in 
wt mice. Given that IL-6 analyses would yield interesting results, it would be informative to 
cross-breed the Pdgfd-/- mice with mice overexpressing IL-6. Possibly, the aggravated hypoxia-
induced PH, seen in the lung specific IL-6 transgenic mice (103), may be attenuated by PDGF-
D ablation.  
Further, as IL-6 has been shown to function as a promigratory signal for pericytes in vascular 
remodeling of PH ((87) and discussed in paper II) , and as paper III found Pdgfd-/- mice to have 
a discrete pericyte phenotype in cardiac vessels, it would be interesting to closer examine 
pericytes in Pdgfd-/- hearts and lungs, both in normoxia and hypoxia. Due to differences 
between animal models, it may be worthwhile to also test a pharmacological approach, e.g. an 
inhibitory antibody, directed against PDGF-D in a rat model of PH. This would better mimic 
the clinical situation since rat models of PH, such as the Sugen-hypoxia model, closer resemble 
the severity of PAH pathology in patients. Also, as opposed to using a full genetic knock out 
approach, administering an agent after onset of disease obviously is closer to the clinical 
situation. 
To our knowledge, the role of PDGF-D had not been previously investigated in PH. In paper 
IV, PDGF-D was found to be present in vascular lesions of idiopathic PAH patients and capable 
of inducing pulmonary arterial SMC proliferation. By a constituent genetic knock out 
approach, utilizing the Pdgfd-/- mice, we found no role of PDGF-D in hypoxia-induced PH. 
This could be model specific and there is a possibility that compensatory alterations account 
for PH development in Pdgfd-/- mice. Given the initial mRNA and miRNA results, continued 
characterization is needed. This would aid in interpreting the role of PDGF-D in PH, if any. 
Noteworthy, further analyses might point to known or unknown central mediators of PH, thus 
suggesting promising future therapeutic targets.  
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5 Conclusions and perspectives 
In conclusion, this PhD thesis states that extracellular positioning of growth factors can direct 
pulmonary vascular remodeling. Thus, the place of PDGF-B matters. PDGF-D was shown to 
be a potent mitogen, present in vascular lesions of PAH patients. However the role of PDGF-
D seems to be redundant, at least in the mouse model of hypoxia-induced PH.  
The different mouse models used, i.e. Hspg2r3/r3 mice with HS deficient perlecan, Pdgfbret/ret 
mice lacking the retention motif of PDGF-B, and Pdgfd-/- mice entirely devoid of PDGF-D, all 
display some phenotype in pericytes. This highlights the already well studied HS-dependence 
of PDGF-B mediated mural cell recruitment and suggest that PDGF-D does exert a similar 
effect.  
Clearly there are limitations to all papers included, and thereby to the thesis as such. One 
limitation is the lack of different timepoints in paper II and IV. After four weeks of chronic 
hypoxia, PH is manifest and cellular activity has reached a plateau. This is exemplified in paper 
II, where proliferation markers were studied after the completion of hypoxia-treatment. It is 
very likely that an earlier time point would have revealed a higher proliferative rate. Further, 
mRNA expression of growth factors and cytokines undoubtedly vary throughout disease 
progression, probably to later stabilize in manifest PH. Therefore, interpretation of 
compensatory regulations in Pdgfbret/ret and Pdgfd-/- mice is somewhat limited and this needs 
to be taken into consideration when concluding results in paper II and IV. Several mRNA 
results would also need to be confirmed on a protein level.  
Further, tissue localization of investigated proteins would add to the understanding, especially 
in the hypoxia-treated Pdgfbret/ret mice. It is not clear to where PDGF-B diffuses. This was 
however hindered due to lack of trustworthy antibodies that would bind PDGF-B of both wt 
and Pdgfbret/ret mice. Neither did we succeed in finding a PDGF-D antibody to reliably stain 
mouse tissue. This was somewhat accounted for by using the Lac-z reporter signal, and an 
alternative to this would be to use RNAscope. However both of these analytical tools only tell 
of the gene expression and not protein localization.  
Further, the use of other animal models of PH would not only yield greater credibility to the 
results, if coherent in several models, but also enable analyses of different aspects of PH 
pathobiology. Nevertheless, the presented work is informative and indeed, fine-tuned 
manipulation of molecular subdomains, as is the case in both paper I and II, could not have 
been performed in any other model than genetically modified mice. To use inducible knock out 
mice would allow for the same analysis, but with the advantage of avoiding possible 
developmental defects. In this case however, one would need to account for that the inducible 
knock out systems available are not fully effective, but leaves a certain proportion of cells 
unaffected.  
Keeping in mind that PAH patients most often die due to RV failure, future perspectives should 
include more precise characterization of cardiac function. However this would preferably not 
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be investigated in such a mild model of PH as the mouse chronic hypoxia model, but rather in 
the rat Sugen-hypoxia model.  
Also, as hypoxia-treated Pdgfbret/ret mice have elevated levels of Il6 mRNA, and Pdgfd-/- mice 
display miRNA alterations suggesting a basis for increased of IL-6 signaling, clearly it would 
be interesting to further investigate to what extent IL-6 is altered and to what extent it 
contributes to the observed pulmonary vascular remodeling. Further, given the pericyte 
phenotype in all three mouse strains investigated and the recent finding of that also IL-6 is 
implicated in pericyte migration and PH development, it would be interesting to explore how 
cross-breeding with lung-specific overexpressing IL-6 mice would alter the phenotypes. Since 
IL-6 overexpression combined with chronic hypoxia is among the most severe model of PH 
known in mice, such future studies would warrant a more in-depth cardiac assessment. 
Ultimately, this thesis prompts future studies on growth factors and cytokines in PAH to take 
the ECM into consideration. Numerous of the implicated mediators of pulmonary vascular 
remodeling are known to bind extracellular proteoglycans. A deepened understanding of the 
spatiotemporal effects could contribute to future medical therapies.  
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